Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
PEMBROLIZUMAB 395 MG-BERAHYALURONID-PMPH 4,800 UNIT/2.4 ML SUBCUT SOLN (NDC 0006-3083-01) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved November 15, 2026 , from http://ppman.hank.ai/transparency/procedure/0006-3083-01/by-state?code_type=NDC
“PEMBROLIZUMAB 395 MG-BERAHYALURONID-PMPH 4,800 UNIT/2.4 ML SUBCUT SOLN (NDC 0006-3083-01) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/0006-3083-01/by-state?code_type=NDC. Accessed
November 15, 2026 .
“PEMBROLIZUMAB 395 MG-BERAHYALURONID-PMPH 4,800 UNIT/2.4 ML SUBCUT SOLN (NDC 0006-3083-01) by State,” HANK Price Transparency ,
accessed November 15, 2026 ,
http://ppman.hank.ai/transparency/procedure/0006-3083-01/by-state?code_type=NDC.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
NDC · across United States
0006-3083-01 — Pembrolizumab 395 Mg-berahyaluronid-pmph 4,800 Unit/2.4 Ml Subcut Soln
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$23,812
National median
$23,812 – $23,812
IQR (p25 – p75)
1
hospitals filing
1
states
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for 0006-3083-01 (NDC), with interquartile range
State Median p25 p75
MD $23,812 $23,812 $23,812